Search
Regeneron Pharmaceuticals Inc
REGNAdd to Watchlist
607.730USD
-7.000-1.14%
Close 06/17, 16:00（ET）Quotes delayed by 15 min
63.73BMarket Cap
14.31P/E TTM
Earnings Forecast
Currency: USD Updated: 2026-06-17The current earnings forecast score of Regeneron Pharmaceuticals Inc is 7.81, ranking 90 out of 157 in the Pharmaceuticals industry. The average price target is 767.00, with a high of 1057.00 and a low of 627.00.
Analyst Rating
Based on
32
analysts
Buy
Current Rating
830.429
Target Price
+35.09%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
175
Total
6
Median
8
Average
Company name
Ratings
Analysts
Regeneron Pharmaceuticals Inc
REGN
32
Biogen Inc
BIIB
38
Amgen Inc
AMGN
38
Eli Lilly and Co
LLY
35
AbbVie Inc
ABBV
34
Vertex Pharmaceuticals Inc
VRTX
34
1
2
3
...
35
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
FAQs
What is Regeneron Pharmaceuticals Inc's expected revenue for the next quarter?
Regeneron Pharmaceuticals Inc's expected revenue is 3.83B.
What is Regeneron Pharmaceuticals Inc's price target?
Analysts forecast that Regeneron Pharmaceuticals Inc's price target is USD 767.00, with the highest forecast at USD 1.06K and the lowest forecast at USD 627.00.
How have Regeneron Pharmaceuticals IncREGN's recent earnings per share performed?
The market expectation was USD 6.99, while Regeneron Pharmaceuticals IncREGN's earnings per share (EPS) for the previous quarter was USD 8.19. EPS for the next quarter is expected at USD 10.85.
What is the analyst rating for Regeneron Pharmaceuticals Inc?
Based on the ratings of Regeneron Pharmaceuticals Inc's stock from 32 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.
